Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

CVS Medicare Part D Plan With Pass-Through Rebates Has Limited Uptake

Low enrollment indicates that beneficiaries have trouble figuring out whether reductions in cost sharing would offset a much higher premium.

Medicare Pharmacy Benefit Management

ICER’s ‘Unsupported Price Increase’ Report Due This Fall

Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.

Pricing Debate Policy

Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests

HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.

Pricing Debate Regulation

House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses

Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.

Pricing Debate Legislation

Louisiana ‘Netflix’ Model For Hepatitis C Drugs Caps Spending At $35m Per Year

Purchasing contract for state Medicaid and Corrections programs would last up to five years and aim to treat more than 10,000 patients in first year.

Pricing Strategies Medicaid

Trulicity DTC Ads Reference Lilly Website For List Price, Cost Sharing Info

In format that industry hopes becomes alternative to government-mandated inclusion of list price on TV, Lilly webpage notes cost sharing associated with 35% of Medicare Part D claims is $180 per month, and is lower for the remaining 65%.  Patients who haven’t met their deductible will see “higher prices.”

Pricing Debate Ad Campaigns
See All
Advertisement
UsernamePublicRestriction

Register